Early-Stage Breast Cancer Clinical Trials: Ultra-Short Radiation & New Approaches Recruiting
A trial at UW Carbone Cancer Center is testing ultra-short whole breast irradiation (5 visits) with simultaneous integrated boost for early-stage breast cancer. Learn about this and other de-escalation radiation trials recruiting now.
Early-Stage Breast Cancer Clinical Trials: Ultra-Short Radiation & New Approaches Recruiting
A breast cancer diagnosis brings urgent decisions: surgery type, radiation, systemic therapy, and whether to join a clinical trial. For women with early-stage (T1-T2, node-negative) breast cancer choosing breast-conserving surgery, radiation therapy is standard—but the duration and intensity are evolving. New trials are testing ultra-short radiation schedules that could reduce treatment from weeks to days.
The Standard: Whole Breast Irradiation (WBI)
Traditionally, WBI after lumpectomy meant 15–25 daily fractions over 3–5 weeks (conventional or hypofractionated). A boost (extra dose to the tumor bed) adds 4–8 more treatments. While effective, this schedule challenges working women, caregivers, and those traveling long distances.
Actively Recruiting: Ultra-Short WBI with Simultaneous Integrated Boost (SIB)
A trial at UW Carbone Cancer Center, Madison, WI (NCT06295744) is evaluating ultra-short WBI with SIB—delivering the whole breast dose and the tumor bed boost simultaneously in just 5 treatment visits.
Study Design
- Population: 50 women, ≥18 years, early-stage (T1-T2) invasive breast cancer or DCIS
- Surgery: Breast-conserving with negative margins, node-negative (N0/Nx)
- Radiation: 3D-CRT or IMRT with simultaneous integrated boost
- Schedule: 5 treatment visits over ~1–2 weeks (vs. 15–25 visits standard)
- Follow-up: 6 weeks, then 12, 24, 36, 48, 60 months (cosmesis, PROMs, toxicity, recurrence)
Why Ultra-Short Radiation Matters
| Standard WBI (15–25 fx) | Ultra-Short WBI + SIB (5 fx) |
|---|---|
| 3–5 weeks daily visits | ~1–2 weeks, 5 visits |
| Separate boost (4–8 fx) | Boost integrated simultaneously |
| Higher travel/time burden | Minimal disruption to work/family |
| Established long-term data | Investigational—long-term outcomes TBD |
Primary endpoint: 2-year cosmetic outcomes (MD-assessed + patient-reported BREAST-Q). Secondary: Acute/late toxicity, local recurrence, overall survival.
Other Recruiting Early-Stage Breast Cancer Trial Categories
| Approach | Examples | Key Question |
|---|---|---|
| De-escalation | Omitting radiation in low-risk genomic profiles (e.g., Oncotype DX low, Ki67 low) | Can we safely skip radiation entirely for some? |
| Partial Breast Irradiation (APBI) | Brachytherapy, intraoperative RT, external beam APBI | Treat only the tumor bed + margin? |
| FAST-Forward / UK Hypofractionation | 5 fractions in 1 week (26 Gy/5 fx) | Non-inferior to 15 fx for local control? |
| Proton Therapy | PBS proton WBI ± boost | Reduced heart/lung dose for left-sided tumors? |
| Neoadjuvant + Response-Adapted | Systemic therapy first → tailor surgery/radiation to response | Can pathologic complete response (pCR) reduce local therapy? |
| Biomarker-Driven | Circulating tumor DNA (ctDNA) to guide adjuvant decisions | Does ctDNA clearance = less radiation needed? |
Finding a Breast Cancer Trial That Fits You
Eligibility hinges on:
- Stage & biology: T1-T2, N0, ER/PR/HER2 status, genomic score
- Surgery: Lumpectomy vs. mastectomy, margin status
- Prior treatment: Neoadjuvant chemo? pCR achieved?
- Anatomy: Breast size, heart/lung distance (for proton/heart-sparing)
- Logistics: Travel to academic center, time off work, support system
Corterve matches you by:
- Precision filtering — "early-stage breast cancer," "DCIS," "triple-negative," "HER2+"
- Location + travel radius — centers near your ZIP
- Structured pre-screen — stage, surgery, receptors, travel willingness (4–6 questions)
- Site referral — direct connection to study coordinator if you pre-qualify
> Important: Radiation trials have strict anatomic and dosimetric criteria. Pre-qualification is a first step only. The radiation oncologist confirms eligibility via CT simulation and dosimetry. Discuss with your breast surgeon and radiation oncologist.
Questions for Your Radiation Oncologist
- Am I a candidate for hypofractionated or ultra-short radiation?
- What are the cosmetic outcome data for my breast size/shape?
- How does left-sided treatment affect heart dose? (Deep inspiration breath hold? Protons?)
- If I had neoadjuvant chemo and achieved pCR, can radiation be omitted or shortened?
- What are the late toxicity risks (fibrosis, telangiectasia, secondary malignancy)?
- How does the trial's follow-up schedule work with my life?
Take the Next Step
Search actively recruiting early-stage breast cancer trials: Corterve Breast Cancer Trials
Search for ultra-short radiation studies: Corterve Radiation Trials
Register for alerts: Get notified when breast cancer trials open at centers near you.
Disclaimer: Corterve is a clinical trial matching platform, not a medical provider. We do not give medical advice, diagnose conditions, or guarantee trial eligibility. All eligibility determinations are made by the study's research team. Breast cancer treatment decisions should be made with your multidisciplinary care team (breast surgeon, medical oncologist, radiation oncologist).